Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.
Davis SL, Messersmith WA, Purcell WT, Lam ET, Corr BR, Leal AD, Lieu CH, O'Bryant CL, Smoots SG, Dus ED, Jordan KR, Serkova NJ, Pitts TM, Diamond JR. Davis SL, et al. Among authors: lam et. Cancers (Basel). 2024 Apr 10;16(8):1456. doi: 10.3390/cancers16081456. Cancers (Basel). 2024. PMID: 38672538 Free PMC article.
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A. Bowles DW, et al. Among authors: lam et. Clin Cancer Res. 2014 Mar 15;20(6):1656-65. doi: 10.1158/1078-0432.CCR-13-2506. Epub 2014 Feb 3. Clin Cancer Res. 2014. PMID: 24493827 Free PMC article. Clinical Trial.
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Diamond JR, et al. Among authors: lam et. Invest New Drugs. 2015 Jun;33(3):691-9. doi: 10.1007/s10637-015-0236-4. Epub 2015 Apr 21. Invest New Drugs. 2015. PMID: 25895965 Clinical Trial.
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.
Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Lam ET, et al. Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20. Mol Cancer Ther. 2018. PMID: 29054986 Free PMC article. Clinical Trial.
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, Gustafson DL, Messersmith WA, Leong S, Eckhardt SG, Pitts TM, Diamond JR. Davis SL, et al. Among authors: lam et. Clin Cancer Res. 2020 Sep 1;26(17):4633-4642. doi: 10.1158/1078-0432.CCR-19-3498. Epub 2020 May 15. Clin Cancer Res. 2020. PMID: 32414750 Free PMC article. Clinical Trial.
A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers.
Ma WW, Zhu M, Lam ET, Diamond JR, Dy GK, Fisher GA, Goff LW, Alberts S, Bui LA, Sanghal A, Kothekar M, Khopade A, Chimote G, Faulkner R, Eckhardt SG, Adjei AA, Jimeno A. Ma WW, et al. Among authors: lam et. Cancer Chemother Pharmacol. 2021 Jun;87(6):779-788. doi: 10.1007/s00280-021-04235-z. Epub 2021 Feb 26. Cancer Chemother Pharmacol. 2021. PMID: 33634324 Clinical Trial.
149 results